Previous 10 | Next 10 |
ATLANTA, July 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces th...
Alimera Sciences (NASDAQ:ALIM) its partner Ocumension Therapeutics received approval from China's National Medical Products Administration (NMPA) for an application seeking to begin a phase 3 trial of fluocinolone acetonide intravitreal implant to treat diabetic macular edema (DME). DME is a ...
ATLANTA, June 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced t...
ATLANTA, June 02, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced t...
ATLANTA, May 12, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced tod...
Alimera Sciences, Inc (ALIM) Q1 2022 Earnings Conference Call May 09, 2022, 9:00 AM ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President and Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital ...
Alimera Sciences press release (NASDAQ:ALIM): Q1 GAAP EPS of -$0.85 misses by $0.16. Revenue of $11.89M (+6.1% Y/Y) misses by $1.01M. For further details see: Alimera Sciences GAAP EPS of -$0.85 misses by $0.16, revenue of $11.89M misses by $1.01M
Consolidated Net Revenue of $11.9 Million Up 6% vs. First Quarter of 2021 U.S. Net Revenue Increased 23% vs. First Quarter of 2021 U.S. End User Demand Up 25% vs. First Quarter of 2021 ATLANTA, May 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc....
ATLANTA, May 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will ...
ATLANTA, April 28, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announ...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
Alimera Sciences (NASDAQ: ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This comp...
Net Revenue up 70% to $23 Million vs. Q1 2023 Global End User Demand Up 23% vs. Q1 2023 Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global p...
ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today it ...